Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 2Phase 2 1Phase 1 1

Status

Completed 219Terminated 50Active not recruiting 32Recruiting 31Withdrawn 23Unknown 19Not yet recruiting 7Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Specimen Handling 17Biopsy 12Magnetic Resonance Spectroscopy 10Cyclophosphamide 9venetoclax 5Etoposide 4Azacitidine 4fludarabine phosphate 3fludarabine 3durvalumab 3X-Rays 3Tacrolimus 3Paclitaxel 3Interleukin-2 3Gemcitabine 3Cisplatin 3Carboplatin 3zanubrutinib 2prednylidene 2deltacortene 2aldesleukin 2Vincristine 2Taxes 2Stem Cell Transplantation 2Rituximab 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Protein Subunit Vaccines 2Prednisone 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Radiotherapy × Clear all
NCT05191667 2025-02-13

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Adlai Nortye Biopharma Co., Ltd.

Phase 1 Suspended
32 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡